Although the fund owns companies across the health care sector, including insurers and equipment makers, a pharmaceutical -
heavy portfolio — about 60 % of Health Care's assets are invested in pharmaceutical and biotech firms — held the fund back
over the past year as those stocks came
under fire during the recent U.S. presidential campaign.